GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+3.83%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$261M
AUM Growth
+$261M
(-14%)
Cap. Flow
-$46.6M
Cap. Flow
% of AUM
-17.84%
Top 10 Holdings %
Top 10 Hldgs %
50.42%
Holding
67
New
9
Increased
18
Reduced
11
Closed
21
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$9.42M |
| 2 |
Sarepta Therapeutics
SRPT
|
$9.01M |
| 3 |
Merus
MRUS
|
$8.75M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$5.91M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$5.09M |
Top Sells
| 1 |
Xenon Pharmaceuticals
XENE
|
$21.6M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$17.3M |
| 3 |
ALLK
Allakos
ALLK
|
$9M |
| 4 |
GH Research
GHRS
|
$7M |
| 5 |
Aldeyra Therapeutics
ALDX
|
$6.15M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $25.6M | 9.16% | 190,000 +70,000 | +58% | +$9.42M |
|
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $15.4M | 5.51% | 325,000 +125,000 | +63% | +$5.91M |
|
3
Cogent Biosciences
COGT
$1.69B
| $14.6M | 5.23% | 1,700,000 +200,000 | +13% | +$1.72M |
|
4
Celldex Therapeutics
CLDX
$1.47B
| $13.5M | 4.85% | 350,000 +95,000 | +37% | +$3.67M |
|
5
RAPT Therapeutics
RAPT
$188M
| $12.9M | 4.61% | 350,000 +100,000 | +40% | +$3.67M |
|
|
6
Merus
MRUS
$4.98B
| $11.1M | 3.99% | 350,000 +275,000 | +367% | +$8.75M |
|
|
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $10.5M | 3.75% | 625,000 -100,000 | -14% | -$1.67M |
|
8
Viridian Therapeutics
VRDN
$1.5B
| $9.89M | 3.54% | 500,000 +150,000 | +43% | +$2.97M |
|
9
Rocket Pharmaceuticals
RCKT
$354M
| $9.28M | 3.32% | 425,000 +75,000 | +21% | +$1.64M |
|
10
Arvinas
ARVN
$568M
| $9.04M | 3.24% | 110,000 -40,000 | -27% | -$3.29M |
|
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $9.01M | 3.23% | +100,000 | New | +$9.01M |
|
12
Zentalis Pharmaceuticals
ZNTL
$122M
| $6.73M | 2.41% | 80,000 +15,000 | +23% | +$1.26M |
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.57M | 2.35% | 300,000 -275,000 | -48% | -$6.02M |
|
14
Vaxcyte
PCVX
$4B
| $5.95M | 2.13% | 250,000 +90,000 | +56% | +$2.14M |
|
15
Amicus Therapeutics
FOLD
$2.34B
| $5.78M | 2.07% | 500,000 +235,000 | +89% | +$2.71M |
|
|
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $5.44M | 1.95% | 250,000 +50,000 | +25% | +$1.09M |
|
|
17
Alnylam Pharmaceuticals
ALNY
$58.5B
| $5.09M | 1.82% | +30,000 | New | +$5.09M |
|
|
VRNA
18
Verona Pharma
VRNA
$9.16B
| $5.04M | 1.81% | 750,000 | – | – |
|
|
WHWK
19
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $4.83M | 1.73% | +200,000 | New | +$4.83M |
|
20
Aclaris Therapeutics
ACRS
$209M
| $4.73M | 1.69% | 325,000 +50,000 | +18% | +$727K |
|
|
CMPS
21
Compass Pathways
CMPS
$424M
| $4.64M | 1.66% | 210,000 +110,000 | +110% | +$2.43M |
|
22
Relmada Therapeutics
RLMD
$37.2M
| $4.51M | 1.61% | 200,000 | – | – |
|
|
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.4M | 1.58% | 30,000 -30,000 | -50% | -$4.4M |
|
24
Leap Therapeutics
LPTX
$12M
| $4.37M | 1.57% | 1,350,000 -300,000 | -18% | -$972K |
|
25
Kezar Life Sciences
KZR
$28.9M
| $4.18M | 1.5% | +250,000 | New | +$4.18M |
|